# OPB-401

Source: https://onco.cc/drugs/opb-401/  
OnCo record `opb-401` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

OPB-401 is an experimental in vivo CAR T-cell therapy from Outpace Bio, in preclinical development for B-cell lymphomas.

## Summary

OPB-401 is an in vivo CAR T-cell therapy from Outpace Bio. An in vivo CAR-T programme against CD19 and CD20; the source gives no further detail. Its furthest stage is preclinical development, for B-cell lymphomas. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: OPB-401
- Modality: In vivo CAR T-cell therapy
- Mechanism: An in vivo CAR-T programme against CD19 and CD20; the source gives no further detail.

## Sources

- Outpace Bio: outpacebio.com: https://outpacebio.com/our-science

## Connected records

- targets: [CD19](https://onco.cc/targets/cd19/), [CD20](https://onco.cc/targets/cd20/)
- companies: [Outpace Bio](https://onco.cc/companies/outpace-bio/)

---
JSON: https://onco.cc/api/v1/entities/opb-401.json